Serum Magnesium Concentration and PTH Levels. Is Long-Term Chronic Hypermagnesemia a Risk Factor for Adynamic Bone Disease?

References

• Alfrey A, Miller N. Bone magnesium pools in uremia. J Clin Invest 1973; 52: 3019–3027
   PubMed Web of Science ®Google Scholar
• Anastassiades E, Howarth D, Howarth J. et al. Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 1993; 8: 846–853
   PubMed Web of Science ®Google Scholar
• Brown E. Extracellular calcium sensing, regulation of parathyroid cell function, and role of calcium and other ions as extracellular (first) messengers. Phvsiol Rev 1991; 71: 371–411
   PubMed Web of Science ®Google Scholar
• Brown E, Thatcher J, Watson E, Leombruno R. Extracellular calcium potentiates the inhibitory effects of magnesium on parathyroid function in dispersed bovine parathyroid cells. Metabolism 1984; 33: 171–487
   PubMed Web of Science ®Google Scholar
• Cholst I, Steinberg S, Tropper P, Fox H, Segre G, Bilezikian J. The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Eng J Med 1984; 310: 1221
   PubMed Web of Science ®Google Scholar
• Coburn J, Slatopolsky E. Vitamin D, parathyroid hormone and the renal osteodystrophies. The Kidnev, 4th ed, B. Brenner, F. Rector. Saunders, Philadelphia 1991; 2036–2120
   Google Scholar
• Cohen-Solal M, Sebert J, Bouadilliez B, et al. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone diseases in hemodialyzed patients. J Clin Endocrinol Metab 1991; 73: S16–S24
   Web of Science ®Google Scholar
• Cohen-Solal M, Sebert J, Boudaillez B, et al. Non-aluminic adynamic bone disease in non dialyzed uremic patients: A new type of osteopathy due to overtreat-ment?. Bone 1992; 13: 1–5
   PubMed Web of Science ®Google Scholar
• Contiguglia S, Alfrey A, Miller N, Butkus D. Total body magnesium excess in chronic renal failure. Lancet 1972; i: 1300–1302
   Google Scholar
• Cournot-Witmer G, Placott J, Bourdean A, et al. Effect of aluminum on bone and cell localization. Kidnev Int 1986; 29(Suppl 18)S37-–S40
   Google Scholar
• de Vernejoul M, Kuntz D, Miravet L, Gueris J, Bielakoff J, Ryckewaert A. Bone histomorphometry in hemodialyzed patients. Metab Bone Dis Relat Res 1981; 3: 175–179
   PubMedGoogle Scholar
• Felsenfeld A. Diabetic renal failure and secondary hyperparathvroidism. Blood purification 1995; 13: 44–46
   Google Scholar
• Felsenfeld A, Rodriguez M, Dunlay R, Llach F. A comparison of parathyroid-gland function in haemodyalisis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant 1991; 6: 244–251
   PubMed Web of Science ®Google Scholar
• Fournier A, Moniere P, Cohen-Solal M, et al. Adynamic bone disease in uremia. May be idiopathic? Is it an actual disease?. Nephron 1991; 58: 1–12
   PubMed Web of Science ®Google Scholar
• Fournier A, Yverneau P, Hue P. et al. Adynamic bone disease in patients with uremia. Curr Op Nephrol Hypertens 1994; 3: 396–410
   PubMedGoogle Scholar
• Gonella M, Calabrese G. Magnesium status in chronically hemodialyzed patients, The role of dyalisate Mg concentration. Magnesium Res 1989; 2: 259–266
   PubMedGoogle Scholar
• Hercz G, Pei Y, Greenwood C, Saiphoo C, et al. Aplastic osteodystrophy without aluminum: the role of suppresed parathvroid function. Kidnev Int 1993; 44: 860–866
   PubMed Web of Science ®Google Scholar
• Hernandez D, Concepcion M, Lorenzo V, et al. Adynamic bone disease with negative aluminum staining in predialysis patients: prevalence and evolution after maintenance hemodialvsis. Nephrol Dial Transplant 1994; 9: 517–523
   PubMed Web of Science ®Google Scholar
• Llach F, Felsenfeld A, Coleman M, Petersen J. Prevalence of various tvpes of bone disease in dialyzed patients. Proceedings of the Ninth International Congress of Nephrology, R Robinson. Springer-Verlag, New York 1984; vol II: 1375–1382
   Google Scholar
• Malluche H, Monier-Faugerc H. Risk of adynamic bone disease in dialyzed patients. Kidnev Int 1992; 42(Suppl 38)S62-–S67
   Google Scholar
• Massry S, Coburn J. Comments on the mechanisms of disordered divalent ion metabolism in renal failure. A possible role of magnesium-depletion. Am J Clin Nutr 1970; 23: 1005–1008
   PubMed Web of Science ®Google Scholar
• Mathias R, Salusky I, Harman W, et al. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital. J Am Soc Nephrol 1993; 3: 1938–1946
   PubMed Web of Science ®Google Scholar
• Morinière P, Cohen-Solal M, Belbrik S, Sebert J, Fournier A. Disappearance of aluminic bone disease in a long-term asymptomatic dialysis population restricting Al(OH)3 intake, Emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 1989; 53: 93–101
   PubMed Web of Science ®Google Scholar
• Moriniére P, Vinatier I, Weskeel, et al. Magnesium hydroxide as a complementary aluminum-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant 1988; 3: 651–656
   PubMed Web of Science ®Google Scholar
• O'Donovan R, Baldwin D, Hammer M, Moniz C. Substitution of aluminum salts by magnesium in control of dialysis hyperphosphataemia. Lancet 1986; 1: 880–881
   PubMed Web of Science ®Google Scholar
• Oe P, Lips P, Wan der Menler J, De Vries P, Van Browwijk H, Donker A. Long term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 1987; 28: 180–185
   PubMed Web of Science ®Google Scholar
• Parsons V, Baldwin D, Moniz C, Mausden J, Ball E, Rifkin I. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders. Nephron 1993; 63: 379–383
   PubMed Web of Science ®Google Scholar
• Pei Y, Hercz G, Greenwood C, et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44: 159–164
   PubMedGoogle Scholar
• Salusky I, Ramirez J, Oppenheim W, Gales B, Segre C, Goodman W. Biochemical markers of renal osteodys trophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45: 253–258
   PubMed Web of Science ®Google Scholar
• Sherrard D, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure–An evolving disorder. Kidney Int 1993; 43: 436–442
   PubMed Web of Science ®Google Scholar
• Sherrard D, Off S, Maloney N, Andress D, Coburn J. Uremic osteodystrophy: classification, cause and treatment. Clinical disorders of Bone and Mineral Metabolism, B Frame, J Potts, Jr. Excerpta Medical, Amsterdam 1983; 254–258
   Google Scholar
• Teitelbaum S L. Renal osteodystrophy. Hum Pathol 1984; 15: 306–323
   PubMed Web of Science ®Google Scholar
• Torres A, Hernández D, Conceptión M, Lorenzo V. Higher levels of intact parathyroid hormone are necessary to maintain a normal bone remodelling in dialysis patients. J Am Soc Nephrol 1992; 3: 677
   Google Scholar
• Torres A, Lorenzo V, Hernández D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better response to PTH. Kidney Int 1995; 47: 1434–1442
   PubMed Web of Science ®Google Scholar
• Vicenti F, Arnaud S, Recker R. Parthyroid and bone response of the diabetic patient to uremia. Kidney Int 1984; 25: 677–682
   PubMed Web of Science ®Google Scholar